Table 1 Descriptive statistics of the entire cohort of participants as segregated according to the type of LND
ePLND during RARP | |||
|---|---|---|---|
Antegrade | Retrograde | p value* | |
No. Patients | 41 | 64 | |
Age (years) | 67 (IQR 62–72.5) | 70 (IQR 64–72) | 0.27 |
BMI (kg/m2) | 25.95 (IQR 24.22–29.76) | 25.45 (IQR 23.53–28.36) | 0.45 |
ASA | 0.34 | ||
I | 15 (36.6%) | 29 (45.3%) | |
II | 23 (56.1%) | 32 (50.0%) | |
III | 3 (7.3%) | 3 (4.7%) | |
Previous abd. surgery | 0.22 | ||
Yes | 23 (56.1%) | 28 (43.8%) | |
No | 18 (43.9%) | 36 (56.3%) | |
Clinical Stage | |||
cT1 | 20 (48.8%) | 30 (46.9%) | 0.78 |
cT2 | 21 (51.2%) | 32 (50.0%) | 0.78 |
cN1 | 1 (2.4%) | 4 (6.3%) | 0.37 |
iPSA | 7.35 (IQR 5.12–10.35) | 6.95 (IQR 4.92–10) | 0.97 |
ISUP grade | 0.99 | ||
1 | 4 (9.8%) | 6 (9.4%) | |
2–3 | 24 (58.5%) | 42 (65.6%) | |
4–5 | 13 (31.7%) | 16 (25%) | |
Pathological stage | 0.31 | ||
pT2b-pT2c | 28 (68.3%) | 40 (62.5%) | |
pT3a | 6 (14.6%) | 11 (17.2%) | |
pT3b | 4 (9.7%) | 5 (7.8%) | |
Lymph nodes | |||
Total number | 20 (IQR 16.25–31.5) | 19 (IQR 15–26.25) | 0.18 |
Positive lymph nodes | 5/41 (12.2%) | 8/64 (12.5%) | 0.96 |
Total OT (min) | 290 (IQR 262–305) | 326 (IQR 301.25–347.5) | < 0.001 |
ePLND time (min) | 33.5 (IQR 29.5–38.5) | 33.5 (IQR 26.5–37.5) | 0.40 |
EBL (ml) | 300 (IQR 195–417.5) | 323 (IQR 200–483) | 0.25 |
Length of stay (days) | 2.50 (IQR 2–3) | 2.50 (IQR 2–3) | 0.93 |
Catheterisation (days) | 7 (IQR 6–9) | 7 (IQR 6–7.75) | 0.71 |
Abdominal drain (days) | 1 (IQR 1–1) | 1 (IQR 1–1) | 0.56 |
Complications | 0.61 | ||
Yes | 8 (19.5%) | 9 (14.1%) | |
No | 33 (80.5%) | 55 (85.9%) | |
Clavien-Dindo | 0.40 | ||
I-II | 6 (14.6%) | 9 (14%) | |
III-IV | 2 (4.9%) | 0 (0%) | |
Lymphocele | 0.30 | ||
Yes | 3 (7.3%) | 1 (1.6%) | |
No | 38 (92.7%) | 63 (98.4%) | |
Fever | 0.51 | ||
Yes | 5 (12.2%) | 5 (7.8%) | |
No | 36 (87.8%) | 59 (92.2%) | |
LND quality | |||
Efficient | 33 (80.5%) | 28 (44%) | 0.01 |
Not efficient | 8 (19.5%) | 36 (56%) | |